Jessie Hanrahan Sells 4,610 Shares of Solid Biosciences Inc. (NASDAQ:SLDB) Stock

Solid Biosciences Inc. (NASDAQ:SLDB) insider Jessie Hanrahan sold 4,610 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $5.60, for a total transaction of $25,816.00. Following the completion of the sale, the insider now owns 14,235 shares in the company, valued at approximately $79,716. This trade represents a 24.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Solid Biosciences Price Performance

Shares of Solid Biosciences stock opened at $4.96 on Friday. The company has a market cap of $198.20 million, a PE ratio of -1.63 and a beta of 2.01. The firm has a fifty day moving average price of $5.90 and a two-hundred day moving average price of $7.21. Solid Biosciences Inc. has a fifty-two week low of $3.35 and a fifty-two week high of $15.05.

Solid Biosciences (NASDAQ:SLDB) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.12). Analysts expect that Solid Biosciences Inc. will post -2.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have issued reports on SLDB. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Solid Biosciences in a report on Thursday, November 7th. William Blair raised shares of Solid Biosciences to a “strong-buy” rating in a research report on Friday, August 30th. Chardan Capital reissued a “buy” rating and set a $15.00 price objective on shares of Solid Biosciences in a research report on Monday, November 11th. Barclays decreased their target price on shares of Solid Biosciences from $18.00 to $15.00 and set an “overweight” rating for the company in a research report on Wednesday, August 14th. Finally, JPMorgan Chase & Co. decreased their price target on Solid Biosciences from $15.00 to $12.00 and set an “overweight” rating for the company in a research note on Tuesday, November 12th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Solid Biosciences currently has an average rating of “Buy” and an average price target of $15.14.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company bought a new stake in shares of Solid Biosciences in the 3rd quarter worth about $71,000. Point72 DIFC Ltd acquired a new stake in Solid Biosciences in the second quarter worth about $58,000. Ground Swell Capital LLC bought a new stake in shares of Solid Biosciences during the second quarter worth approximately $76,000. MetLife Investment Management LLC raised its position in shares of Solid Biosciences by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 13,699 shares of the company’s stock valued at $95,000 after acquiring an additional 7,719 shares during the last quarter. Finally, Algert Global LLC bought a new stake in Solid Biosciences in the second quarter valued at about $82,000. Institutional investors own 81.46% of the company’s stock.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.